Compare State Street SPDR S&P Homebuilders ETF (XHB) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Homebuilders ETF vs Zoetis Inc — how do they compare? State Street SPDR S&P Homebuilders ETF trades at $94.77 (market cap $1.49B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 20.3× State Street SPDR S&P Homebuilders ETF's market cap, and Zoetis Inc pays a 2.9% dividend while State Street SPDR S&P Homebuilders ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR S&P Homebuilders ETF for 33 Days and Zoetis Inc for 70 Days on average.
| XHB | ZTS | |
|---|---|---|
Market Cap | $1.49B | $30.20B |
Volume | 2,445,587 | 6,175,327 |
Sector | Broad Market / Factor | Health |
52-Week High | $121.36 | $147.53 |
52-Week Low | $94.86 | $69.09 |
Typical Hold Time | 33 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XHB (SPDR S&P Homebuilders ETF) trades at $95.66, up 0.81% with a bearish technical signal from moving averages. The ETF faces headwinds from rising mortgage rates above 7% but shows potential as homebuilder valuations signal historical buying opportunities. Recent housing data shows mixed signals with new home sales rising 1.6% in June while existing home sales declined 2.4%.
The ETF presents a contrarian opportunity as battered homebuilder stocks may rebound if housing affordability improves. Key risks include persistent high mortgage rates and economic uncertainty. Institutional activity shows mixed signals with Greenland Capital's $17.33 million investment contrasting CoreCap's 99.3% position reduction.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
